Latest Information Update: 01 Sep 2009
At a glance
- Originator Johnson & Johnson
- Class Antiasthmatics
- Mechanism of Action Chymase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 04 Sep 2007 Phase-I clinical trials in Asthma in USA (PO)
- 16 Jan 2007 Preclinical trials in Asthma in USA (unspecified route)